Ireland
--:--IST
Active, not recruiting Observational

Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term

NCT04003922 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2020-04-21
Last updated
2026-10-28

Condition(s) studied

Rasmussen Encephalitis

Investigational drug(s) / intervention(s)

Adalimumab treatment

Adalimumab treatment: Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.

Study summary

Since the initial study of cases reported between 2009 and 2015, adalimumab has become in France the immunomodulatory reference treatment used after failure of corticosteroids and immunoglobulins before a possible recourse to the hemispherotomy. This observational study is intended to document the long-term efficacy and safety of Adalimumab therapy in patients with Rasmussen encephalitis.

Eligibility

Sex
ALL
Min age
2 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of Rasmussen Encephalitis * Patient aged more than 2 years * Compliant treatment with adalimumab Exclusion Criteria: * Patient with a differential diagnosis * Patient suffering from Rassmussen Encephalitis but not treated with adalimumab * Patient who has not signed the informed consent

Primary outcome measure(s)

  • Efficiency of the treatment measured by the reduction of the number of epileptic seizures — 5 years
    The change of epileptic seizures (Will be considered as a responder patient any patient with a 50% decrease in the number of seizures between the time of inclusion and 6 months after the start of treatment). This response to treatment is re-evaluated at 12 months then every 6 months for 5 years.
  • Efficiency of the treatment measured by the stability if the cognitive assessment — 6 months
    Stability of the cognitive assessment: variation of less than 10 points on each of the different composite indices (QIT, ICV, IRF, IMT, IVT) of age-appropriate Weschler scales, between two cognitive assessments of 6 months.

Trial sites (1)

FacilityCityRegionStatus
Service Neuropédiatrie Marseille France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04003922 on ClinicalTrials.gov ↗ ← All trials in France